CareDx together with its subsidiaries, is a medicine company focused on the discovery, development and commercialization of diagnostic solutions for transplant patients and caregivers. Co. provides testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey, and is a provider of genomics-based information for transplant patients. Co.'s commercially available testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, AlloMap® Heart, a solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure® Lung. The CDNA stock yearly return is shown above.
The yearly return on the CDNA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CDNA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|